Inspire Medical Systems delivered strong third-quarter results, with revenue reaching $224.5 million, a 10% increase from the prior year. The company achieved a gross margin of 85.8% and reported a net income of $9.9 million, with adjusted diluted EPS of $0.38. Inspire is making significant progress with the U.S. launch of its Inspire V system and has reaffirmed its full-year revenue guidance while raising its diluted net income per share guidance.

Inspire Medical Systems reported second quarter 2025 revenue of $217.1 million, an 11% increase from the prior year. Despite the revenue growth, the company experienced a net loss of $3.6 million and an operating loss of $3.3 million, primarily due to increased operating expenses and a non-cash impairment. Adjusted net income was $13.3 million, and adjusted diluted EPS was $0.45.

Inspire Medical Systems reported strong performance in the first quarter of 2025 with revenue growth of 23% year-over-year, reaching $201.3 million. The company achieved a net income of $3.0 million and diluted earnings per share of $0.10, showing significant improvement compared to a net loss in the prior year period. Gross margin remained strong at 84.7%, and operating loss improved by 90%. The company also surpassed a milestone of 100,000 patients receiving Inspire therapy.

Inspire Medical Systems reported strong Q4 2024 results, achieving $239.7 million in revenue, a 25% year-over-year increase. Net income rose significantly to $35.2 million, with a diluted EPS of $1.15. Operating income surged to $31.9 million, supported by an 85.0% gross margin. The company activated 72 new U.S. centers and added 12 new sales territories, contributing to growth momentum.

Inspire Medical Systems reported a 33% year-over-year revenue increase to $203.2 million and earnings per share of $0.60 in the third quarter of 2024. The company is increasing its full year revenue guidance to $793 million to $798 million and raising its full year earnings per share guidance to $1.20 to $1.40.

Inspire Medical Systems reported a 30% year-over-year increase in revenue for the second quarter of 2024, reaching $195.9 million. The company achieved an 84.8% gross margin and generated $5.1 million in operating income, with earnings per share of $0.32. Due to these strong results, Inspire has increased its full-year revenue and earnings per share guidance.

Inspire Medical Systems reported a strong first quarter with a 28% year-over-year revenue growth, reaching $164.0 million. The company is increasing its full year 2024 revenue guidance and expects to be profitable for the full year.

Inspire Medical Systems announced a 40% increase in revenue for the fourth quarter of 2023, reaching $192.5 million. The company reported a net income of $14.8 million, or $0.49 per diluted share, and expanded its U.S. presence by adding 78 new medical centers and 13 new sales territories. They reaffirm full year 2024 revenue to be in the range of $775 million to $785 million.

Inspire Medical Systems reported a 40% year-over-year revenue increase in Q3 2023, reaching $153.3 million. The company also activated 62 new centers and created 13 new U.S. sales territories. They are increasing full-year revenue guidance to $608 to $612 million.

Inspire Medical Systems reported a strong second quarter with a 65% increase in revenue compared to the same quarter last year. The company also raised its full-year 2023 revenue guidance to between $600 million and $610 million.

Inspire Medical Systems reported an 84% year-over-year revenue increase in Q1 2023, reaching $127.9 million. The company expanded its reach with new centers and sales territories, while also achieving key milestones such as FDA approval for pediatric patients with Down syndrome and countrywide reimbursement in Belgium. They are raising their full year 2023 revenue guidance to between $580 million to $590 million.

Inspire Medical Systems reported strong third-quarter results with a 77% increase in revenue compared to the previous year, driven by increased utilization at existing sites and expansion of implanting centers and sales territories. The company is raising its full-year 2022 revenue guidance to $384 million to $388 million.